Clinical trials and experimental

Psoriasis is a chronic inflammatory disease characterized by immune-mediated keratinocyte marked proliferation. It is known that there is a direct relationship between psoriasis and metabolic syndrome, BMI is one of the diagnostic criteria of the syndrome in established relationship with psoriasis. Leptin is an adipocyte secreted protein, its values correlated with the IMC2,3. It is also known the leptin involvement in inflammation.
Study that enrolled 78 patients, aiming to evaluate changes in leptin plasma levels in patients with psoriasis plaque and metabolic syndrome that are under various treatments, but also correlate these values with effective therapies and establishing a statistically significant relationship between variations in serum levels of leptin and inflammatory disease development in the metabolic syndrome context.
There was a statistically significant reduction in leptin levels in patients whose disease activity is reduced, for example those who achieved PASI 75 score in 24 treatment weeks. The decrease in some cases of leptin normalize was found among those who followed biological systemic therapy, even patients who achieved only PASI 50 in the 24 weeks of study. The non-biological systemic therapy (methotrexate, PUVA) showed reductions in leptin values, higher in those with PASI 75.
By evaluating plasma levels of leptin variations related to treatment followed by patients with psoriasis vulgaris and metabolic syndrome have managed to prove its importance as a inflammatory marker and therefore a therapeutically efficiency, but also as a predictive factor for cardiovascular and metabolic complications usually associated with prolonged systemic inflammation.